Main variables;Main activity, secondary one or a tool necessary for production;Total
Companies that carry out R&D in Biotechnology;Total;1.198
Companies that carry out R&D in Biotechnology;Main;644
Companies that carry out R&D in Biotechnology;Secondary dwellings;171
Companies that carry out R&D in Biotechnology;Tool;383
%Companies according to biotechnology used: Genetic code;Total;33,3
%Companies according to biotechnology used: Genetic code;Main;40,9
%Companies according to biotechnology used: Genetic code;Secondary dwellings;24
%Companies according to biotechnology used: Genetic code;Tool;24,8
%Companies according to biotechnology used: Functional units;Total;39,8
%Companies according to biotechnology used: Functional units;Main;44,2
%Companies according to biotechnology used: Functional units;Secondary dwellings;38,1
%Companies according to biotechnology used: Functional units;Tool;33,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;24,2
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Main;28,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Secondary dwellings;14,2
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Tool;20,8
%Companies according to biotechnology used: Bioprocesses;Total;49,6
%Companies according to biotechnology used: Bioprocesses;Main;42,6
%Companies according to biotechnology used: Bioprocesses;Secondary dwellings;52,3
%Companies according to biotechnology used: Bioprocesses;Tool;60,2
%Companies according to biotechnology used: Sub-cellular organisms;Total;6,7
%Companies according to biotechnology used: Sub-cellular organisms;Main;8,7
%Companies according to biotechnology used: Sub-cellular organisms;Secondary dwellings;5,8
%Companies according to biotechnology used: Sub-cellular organisms;Tool;3,6
%Companies according to biotechnology used: Bio-computing;Total;23,9
%Companies according to biotechnology used: Bio-computing;Main;33,5
%Companies according to biotechnology used: Bio-computing;Secondary dwellings;13
%Companies according to biotechnology used: Bio-computing;Tool;12,7
%Companies according to biotechnology used: Nanobiotechnology;Total;11,2
%Companies according to biotechnology used: Nanobiotechnology;Main;14,5
%Companies according to biotechnology used: Nanobiotechnology;Secondary dwellings;13,4
%Companies according to biotechnology used: Nanobiotechnology;Tool;4,7
%Companies according to biotechnology used: Other;Total;14,6
%Companies according to biotechnology used: Other;Main;14,4
%Companies according to biotechnology used: Other;Secondary dwellings;19,9
%Companies according to biotechnology used: Other;Tool;12,6
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;47,3
%Company by field(s) of ultimate application of biotechnology use: Human Health;Main;62,8
%Company by field(s) of ultimate application of biotechnology use: Human Health;Secondary dwellings;35,1
%Company by field(s) of ultimate application of biotechnology use: Human Health;Tool;26,7
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;19,4
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Main;21,7
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Secondary dwellings;17,8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Tool;16,2
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;32,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Main;26,1
%Company by field(s) of ultimate application of biotechnology use: Food products;Secondary dwellings;30,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Tool;44,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;24,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Main;20,7
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Secondary dwellings;31,8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Tool;26,5
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;14,9
%Company by field(s) of ultimate application of biotechnology use: Environment;Main;12,8
%Company by field(s) of ultimate application of biotechnology use: Environment;Secondary dwellings;28,9
%Company by field(s) of ultimate application of biotechnology use: Environment;Tool;12,3
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;12,8
%Company by field(s) of ultimate application of biotechnology use: Industry;Main;12,8
%Company by field(s) of ultimate application of biotechnology use: Industry;Secondary dwellings;17,8
%Company by field(s) of ultimate application of biotechnology use: Industry;Tool;10,6
Personnel in R&D in biotechnology (no. of persons);Total;13.615
Personnel in R&D in biotechnology (no. of persons);Main;8.038
Personnel in R&D in biotechnology (no. of persons);Secondary dwellings;1.812
Personnel in R&D in biotechnology (no. of persons);Tool;3.765
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;7.436
Personnel in R&D in biotechnology (no. of persons): Researchers;Main;4.561
Personnel in R&D in biotechnology (no. of persons): Researchers;Secondary dwellings;1.031
Personnel in R&D in biotechnology (no. of persons): Researchers;Tool;1.845
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;6.178
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Main;3.477
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Secondary dwellings;781
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Tool;1.920
Personnel in R&D in biotechnology (no. of persons): women;Total;7.639
Personnel in R&D in biotechnology (no. of persons): women;Main;4.718
Personnel in R&D in biotechnology (no. of persons): women;Secondary dwellings;918
Personnel in R&D in biotechnology (no. of persons): women;Tool;2.003
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;4.095
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Main;2.582
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Secondary dwellings;540
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Tool;973
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;3.544
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Main;2.136
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Secondary dwellings;378
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Tool;1.030
Personnel in R&D in biotechnology (FTE);Total;9.365,2
Personnel in R&D in biotechnology (FTE);Main;5.985,1
Personnel in R&D in biotechnology (FTE);Secondary dwellings;1.120,4
Personnel in R&D in biotechnology (FTE);Tool;2.259,7
Personnel in R&D in biotechnology (FTE): Researchers;Total;5.410,6
Personnel in R&D in biotechnology (FTE): Researchers;Main;3.550,1
Personnel in R&D in biotechnology (FTE): Researchers;Secondary dwellings;695,8
Personnel in R&D in biotechnology (FTE): Researchers;Tool;1.164,8
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;3.954,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Main;2.435
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Secondary dwellings;424,6
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Tool;1.095
Personnel in R&D in biotechnology (FTE): women;Total;5.385,8
Personnel in R&D in biotechnology (FTE): women;Main;3.561,4
Personnel in R&D in biotechnology (FTE): women;Secondary dwellings;597,6
Personnel in R&D in biotechnology (FTE): women;Tool;1.226,7
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;3.032,9
Personnel in R&D in biotechnology (FTE): (women) Researchers;Main;2.028,8
Personnel in R&D in biotechnology (FTE): (women) Researchers;Secondary dwellings;372,1
Personnel in R&D in biotechnology (FTE): (women) Researchers;Tool;632
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;2.352,9
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Main;1.532,6
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Secondary dwellings;225,6
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Tool;594,7
Internal expenditure on R&D (thousands of euros);Total;940.230
Internal expenditure on R&D (thousands of euros);Main;671.106
Internal expenditure on R&D (thousands of euros);Secondary dwellings;84.012
Internal expenditure on R&D (thousands of euros);Tool;185.112
1) By nature of the expense: Current expenses;Total;871.813
1) By nature of the expense: Current expenses;Main;624.784
1) By nature of the expense: Current expenses;Secondary dwellings;75.356
1) By nature of the expense: Current expenses;Tool;171.672
1.1) Remuneration to researchers;Total;284.936
1.1) Remuneration to researchers;Main;194.490
1.1) Remuneration to researchers;Secondary dwellings;33.985
1.1) Remuneration to researchers;Tool;56.460
1.2) Remuneration to technicians and assistants;Total;148.254
1.2) Remuneration to technicians and assistants;Main;96.140
1.2) Remuneration to technicians and assistants;Secondary dwellings;14.239
1.2) Remuneration to technicians and assistants;Tool;37.875
1.3) Other current expenses;Total;438.623
1.3) Other current expenses;Main;334.154
1.3) Other current expenses;Secondary dwellings;27.132
1.3) Other current expenses;Tool;77.337
2) By nature of the expense: Capital expenses;Total;68.417
2) By nature of the expense: Capital expenses;Main;46.322
2) By nature of the expense: Capital expenses;Secondary dwellings;8.656
2) By nature of the expense: Capital expenses;Tool;13.440
2.1) Land and buildings;Total;11.763
2.1) Land and buildings;Main;6.204
2.1) Land and buildings;Secondary dwellings;2.874
2.1) Land and buildings;Tool;2.685
2.2) Equipment and instruments;Total;39.641
2.2) Equipment and instruments;Main;24.588
2.2) Equipment and instruments;Secondary dwellings;5.378
2.2) Equipment and instruments;Tool;9.674
2.3) Acquisition of specific R+D software;Total;2.831
2.3) Acquisition of specific R+D software;Main;1.735
2.3) Acquisition of specific R+D software;Secondary dwellings;319
2.3) Acquisition of specific R+D software;Tool;777
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;14.183
2.4) Otros productos de propiedad intelectual específicos para I+D;Main;13.794
2.4) Otros productos de propiedad intelectual específicos para I+D;Secondary dwellings;85
2.4) Otros productos de propiedad intelectual específicos para I+D;Tool;303
1.1) By origin of the funds: Own funds;Total;577.287
1.1) By origin of the funds: Own funds;Main;421.224
1.1) By origin of the funds: Own funds;Secondary dwellings;39.177
1.1) By origin of the funds: Own funds;Tool;116.886
1.2) By origin of the funds: From companies;Total;142.672
1.2) By origin of the funds: From companies;Main;96.993
1.2) By origin of the funds: From companies;Secondary dwellings;8.211
1.2) By origin of the funds: From companies;Tool;37.467
1.3) By origin of the funds: Public Administration funds;Total;102.630
1.3) By origin of the funds: Public Administration funds;Main;64.741
1.3) By origin of the funds: Public Administration funds;Secondary dwellings;18.219
1.3) By origin of the funds: Public Administration funds;Tool;19.670
1.4) By origin of the funds: From Universities;Total;457
1.4) By origin of the funds: From Universities;Main;453
1.4) By origin of the funds: From Universities;Secondary dwellings;0
1.4) By origin of the funds: From Universities;Tool;5
1.5) By origin of the funds: From non profit private institutions;Total;9.631
1.5) By origin of the funds: From non profit private institutions;Main;8.141
1.5) By origin of the funds: From non profit private institutions;Secondary dwellings;195
1.5) By origin of the funds: From non profit private institutions;Tool;1.294
1.6) By origin of the funds: Foreign funds;Total;107.553
1.6) By origin of the funds: Foreign funds;Main;79.554
1.6) By origin of the funds: Foreign funds;Secondary dwellings;18.210
1.6) By origin of the funds: Foreign funds;Tool;9.790
Purchase of R&D services in biotechnology (thousands of euros);Total;114.839
Purchase of R&D services in biotechnology (thousands of euros);Main;87.621
Purchase of R&D services in biotechnology (thousands of euros);Secondary dwellings;15.855
Purchase of R&D services in biotechnology (thousands of euros);Tool;11.363
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;69.258
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Main;50.862
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Secondary dwellings;13.073
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Tool;5.324
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;45.581
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Main;36.760
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Secondary dwellings;2.782
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Tool;6.039
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;41,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Main;48,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Secondary dwellings;36,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Tool;33
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Main;9,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Secondary dwellings;16,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Tool;14,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Main;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Secondary dwellings;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Tool;14,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;10,7
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Main;10,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Secondary dwellings;10,3
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Tool;10,5
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;Total;15
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;Main;16
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;Secondary dwellings;15
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of access to international markets;Tool;14
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;Main;18
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;Secondary dwellings;16
%Companies that consider the following obstacles as very important considering biotechnology development : Lack of distribution and sales channels;Tool;12
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;Main;15
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;Secondary dwellings;19
%Companies that consider the following obstacles as very important considering biotechnology development : Acceptance / public perception;Tool;17
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;37
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Main;41
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Secondary dwellings;38
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Tool;31
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;Total;51
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;Main;56
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;Secondary dwellings;50
%Companies that consider the following obstacles as very important considering biotechnology development : Time / cost;Tool;43
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;19
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Main;17,4
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Secondary dwellings;18,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Tool;21,8
% Companies that have requested biotechnology patents;Total;18
% Companies that have requested biotechnology patents;Main;26
% Companies that have requested biotechnology patents;Secondary dwellings;14
% Companies that have requested biotechnology patents;Tool;8
Number of patents requested;Total;643
Number of patents requested;Main;471
Number of patents requested;Secondary dwellings;54
Number of patents requested;Tool;118
% Companies with income of an international origin related to biotechnological activities;Total;24,4
% Companies with income of an international origin related to biotechnological activities;Main;30,7
% Companies with income of an international origin related to biotechnological activities;Secondary dwellings;15,3
% Companies with income of an international origin related to biotechnological activities;Tool;17,9
% Turnover representing income of an international origin related to biotechnological activities;Total;1,6
% Turnover representing income of an international origin related to biotechnological activities;Main;8,5
% Turnover representing income of an international origin related to biotechnological activities;Secondary dwellings;0
% Turnover representing income of an international origin related to biotechnological activities;Tool;1,5
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;56
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;Main;61
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;Secondary dwellings;60
% Income of of an international origin related to biotechnological activities distributed in: Income received from the EU;Tool;40
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;44
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;Main;39
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;Secondary dwellings;40
% Income of of an international origin related to biotechnological activities distributed in: Income received from other countries;Tool;60
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;70
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Main;79
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Secondary dwellings;73
% Income of of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Tool;44
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;23,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;18,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary dwellings;0,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool;41,4
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;5,3
% Income of an international origin related with activities according to the classification: Operating source abroad;Main;1,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Secondary dwellings;26,7
% Income of an international origin related with activities according to the classification: Operating source abroad;Tool;14,5
% Income of an international origin related with activities according to the classification: Other;Total;0,6
% Income of an international origin related with activities according to the classification: Other;Main;0,8
% Income of an international origin related with activities according to the classification: Other;Secondary dwellings;0
% Income of an international origin related with activities according to the classification: Other;Tool;0,1